Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Cannabinoid receptor 1 gene polymorphisms and nonalcoholic Fatty liver disease in women with polycystic ovary syndrome and in healthy controls.

Kuliczkowska Plaksej J, Laczmanski L, Milewicz A, Lenarcik-Kabza A, Trzmiel-Bira A, Zaleska-Dorobisz U, Lwow F, Hirnle L.

Int J Endocrinol. 2014;2014:232975. doi: 10.1155/2014/232975. Epub 2014 Jul 17.

2.

Selected CNR1 polymorphisms and hyperandrogenemia as well as fat mass and fat distribution in women with polycystic ovary syndrome.

Jędrzejuk D, Laczmański L, Kuliczkowska J, Lenarcik A, Trzmiel-Bira A, Hirnle L, Dorobisz U, Milewicz A, Lwow F, Urbanovych A, Słoka N.

Gynecol Endocrinol. 2015 Jan;31(1):36-9. doi: 10.3109/09513590.2014.946899. Epub 2014 Aug 5.

PMID:
25093427
3.

Endocannabinoid type 1 receptor gene (CNR1) polymorphisms (rs806381, rs10485170, rs6454674, rs2023239) and cardiovascular risk factors in postmenopausal women.

Łaczmański Ł, Milewicz A, Dunajska K, Jędrzejczuk D, Pawlak M, Lwow F.

Gynecol Endocrinol. 2011 Dec;27(12):1023-7. doi: 10.3109/09513590.2011.569796. Epub 2011 Apr 11.

PMID:
21480765
4.

Uremic Pruritus Is Not Associated with Endocannabinoid Receptor 1 Gene Polymorphisms.

Heisig M, Łaczmański Ł, Reich A, Lwow F, Szepietowski JC.

Biomed Res Int. 2016;2016:3567527. doi: 10.1155/2016/3567527. Epub 2016 Feb 29.

5.

Prevalence of hepatic steatosis in women with polycystic ovary syndrome.

Karoli R, Fatima J, Chandra A, Gupta U, Islam FU, Singh G.

J Hum Reprod Sci. 2013 Jan;6(1):9-14. doi: 10.4103/0974-1208.112370.

6.

Nonalcoholic fatty liver disease and polycystic ovary syndrome.

Vassilatou E.

World J Gastroenterol. 2014 Jul 14;20(26):8351-63. doi: 10.3748/wjg.v20.i26.8351. Review.

7.

Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease.

Vassilatou E, Vassiliadi DA, Salambasis K, Lazaridou H, Koutsomitopoulos N, Kelekis N, Kassanos D, Hadjidakis D, Dimitriadis G.

Eur J Endocrinol. 2015 Dec;173(6):739-47. doi: 10.1530/EJE-15-0567. Epub 2015 Sep 4.

PMID:
26340970
8.

Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?

Targher G, Rossini M, Lonardo A.

Endocrine. 2016 Feb;51(2):211-21. doi: 10.1007/s12020-015-0640-8. Epub 2015 May 30. Review.

PMID:
26024975
9.

The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects.

Dinu IR, Popa S, Bîcu M, Moţa E, Moţa M.

Rom J Intern Med. 2009;47(1):9-18.

PMID:
19886064
10.

The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome.

Sarkar M, Terrault N, Duwaerts CC, Tien P, Cedars MI, Huddleston H.

Curr Opin Gynecol Obstet. 2018 Feb 20;1(1):24-33. Epub 2018 Apr 5.

11.

Polycystic ovary syndrome susceptibility single nucleotide polymorphisms in women with a single PCOS clinical feature.

Cui L, Li G, Zhong W, Bian Y, Su S, Sheng Y, Shi Y, Wei D, Zhang W, Zhao H, Chen ZJ.

Hum Reprod. 2015 Mar;30(3):732-6. doi: 10.1093/humrep/deu361. Epub 2015 Jan 12.

PMID:
25586784
12.

Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF, Arrese M.

J Hepatol. 2007 Sep;47(3):412-7. Epub 2007 May 24.

PMID:
17560682
13.
14.

Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C, Lambrinoudaki I, Georgopoulos NA, Vryonidou A.

Endocrine. 2019 Sep 19. doi: 10.1007/s12020-019-02085-7. [Epub ahead of print] Review.

PMID:
31538291
15.

Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Kelley CE, Brown AJ, Diehl AM, Setji TL.

World J Gastroenterol. 2014 Oct 21;20(39):14172-84. doi: 10.3748/wjg.v20.i39.14172. Review.

16.

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL.

Clin Endocrinol (Oxf). 2014 Oct;81(4):523-8. doi: 10.1111/cen.12369. Epub 2013 Dec 12.

PMID:
24256515
17.

Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome.

Markou A, Androulakis II, Mourmouris C, Tsikkini A, Samara C, Sougioultzis S, Piaditis G, Kaltsas G.

Fertil Steril. 2010 Mar 1;93(4):1220-6. doi: 10.1016/j.fertnstert.2008.12.008. Epub 2009 Jan 26.

PMID:
19171337
18.

Cannabinoid receptor 1 gene is associated with alcohol dependence.

Marcos M, Pastor I, de la Calle C, Barrio-Real L, Laso FJ, González-Sarmiento R.

Alcohol Clin Exp Res. 2012 Feb;36(2):267-71. doi: 10.1111/j.1530-0277.2011.01623.x. Epub 2011 Nov 15.

PMID:
22085192
19.

Abdominal Obesity as a Predictive Factor of Nonalcoholic Fatty Liver Disease Assessed by Ultrasonography and Transient Elastography in Polycystic Ovary Syndrome and Healthy Women.

Tantanavipas S, Vallibhakara O, Sobhonslidsuk A, Phongkitkarun S, Vallibhakara SA, Promson K, Sophonsritsuk A.

Biomed Res Int. 2019 Aug 4;2019:9047324. doi: 10.1155/2019/9047324. eCollection 2019.

20.

Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome.

Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA.

Arq Gastroenterol. 2015 Apr-Jun;52(2):117-23. doi: 10.1590/S0004-28032015000200008.

Supplemental Content

Support Center